Data from: Differentiating founder and chronic HIV envelope sequences

John M. Murray, Stephen Maher, Talia Mota, Kazuo Suzuki, Anthony D. Kelleher, Rob J. Center & Damian Purcell
Significant progress has been made in characterizing broadly neutralizing antibodies against the HIV envelope glycoprotein Env, but an effective vaccine has proven elusive. Vaccine development would be facilitated if common features of early founder virus required for transmission could be identified. Here we employ a combination of bioinformatic and operations research methods to determine the most prevalent features that distinguish 78 subtype B and 55 subtype C founder Env sequences from an equal number of...
1 citation reported since publication in 2018.
146 views reported since publication in 2018.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
19 downloads reported since publication in 2018.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?